PHARMACY

Cefaly Technology relaunches Rx-only migraine wearable

BY Michael Johnsen

NEW YORK – Cefaly Technology on Monday relanuched its "wearable" for the treatment of migraines after undergoing a massive makeover, the company announced.

Cefaly I, which gained popularity for its unique headband-like shape, is now three-quarters its size, fits in the palm of a person's hand, is rechargeable, uses magnets to stay in place and allows patients more control over the intensity of their daily session. The new Cefaly II, is available exclusively in the United States; it will become available next in Europe in September.

"This compact device is so easy to tuck in a pocket or purse and I am hopeful it will further increase compliance and bring an even larger reduction in migraine attacks to patients," stated Pierre Rigaux, CEO Cefaly Technology.  "Cefaly I has a tremendous success record. In clinical trials 81% of compliant patients showed a significant reduction in migraine attacks and up to a 75% reduction in consumption of migraine medications. Now that the device is so small, it's a big deal because patients can have their Cefaly II with them wherever they go, which means they'll be able to use it more readily, at their most convenient time."

Cefaly is an electronic, battery-powered, device that is placed on the forehead for 20-minutes once a day, using a self-adhesive electrode and a magnetic connection. The device sends tiny electrical impulses through the skin to desensitize the upper branches of the trigeminal nerve and reduce the frequency of migraine attacks. The new device allows patients to control their session by ramping up the intensity to their desired comfort level. Also, the introduction of a magnetic connection means the device will more quickly fall into place  – and more securely maintain its connection – rather than be affixed to a fastener where a small movement could occasionally interrupt the session.

Also new is a built-in rechargeable Lithium-ion Polymer 3.7 V battery that replaces the two AAA batteries, which contributed to the device's shape and bulk. The new battery allows for the Cefaly II to be charged either by a USB cable on a home or work computer, or through a wall charger.

The new pocket-sized Cefaly II device includes a USB cable, wall charger, a storage case and one electrode. The device costs $349 and comes with a 60-day money back guarantee.

A pack of three electrodes costs $25; each electrode may be re-used up to 20 times.

Cefaly II is available by prescription-only and indicated for patients 18 years of age and older. Women who are pregnant or could become pregnant should check with their doctor before using Cefaly. In clinical trials, only 4.3% of people reported side effects – all of which were minor and fully reversible.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Walmart Clinic’s Sandra Ryan recognized for lifetime achievement

BY Michael Johnsen

KEYSTONE, Colo. – Sandra Ryan, VP Walmart Care Clinics, was recognized for her visionary leadership with more than 25 years of leadership experience in various clinical, management and leadership settings by the National Nurse Practitioners Symposium with the  Loretta C. Ford Lifetime Achievement Award, Walmart announced on LinkedIn.

The Loretta C. Ford Lifetime Achievement Award is presented annually by the National Nurse Practitioner Symposium to one individual that has demonstrated longevity, integrity, professional achievement and advocacy in advanced practice nursing on a national level.

Ryan received the award from the honor's namesake. Ford is an American nurse and the co-founder of the first nurse practitioner program. She is also a mentor for Ryan. "She is essentially a pioneer, innovator, and inspiring leader of this particular movement," Ford said. "There is no one I know who has made more contribution and deserves more credit or recognition than Sandra Ryan."
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

ANI launches generic Nilandron

BY David Salazar
BAUDETTE, Minn. — ANI Pharmaceuticals on Monday announced the immediate launch of its generic of Nilandron (nilutamide) tablets following the Food and Drug Administration’s approval of the drug. This is the first generic of the drug, which is indicated to treat metastatic prostate cancer in combination with surgical castration. 
 
Nilandron had trailing 12-month sales of $23 million according to IMS Health. 
 
“The nilutamide approval exemplifies ANI's strategic focus to introduce high barrier niche generic products,” ANI president Arthur Przybyl said. “We are excited to have secured approval for a first-to-market generic that represents ANI's second entry into the anti-cancer market and leverages our specialized high-potent manufacturing capability at our plant in Baudette, MN.”
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?